12 Month Price Forecast For BDX
Distance to BDX Price Forecasts
BDX Price Momentum
🤔 Considering BD (BDX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 3:21 AM UTC
BDX Analyst Ratings & Price Targets
Based on our analysis of 22 Wall Street analysts, BDX has a consensus that is bullish. The median price target is $275.00, with forecasts ranging from $245.00 to $327.54. Currently, there are 15 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
With BDX currently trading at $237.92, the median price forecast suggests a 15.6% upside. The most optimistic forecast comes from at , projecting a 37.7% upside, while Jason Bednar at Piper Sandler provides the most conservative target, suggesting a 3.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BDX Analyst Consensus
BDX Price Target Range
Latest BDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 1, 2024 | Citigroup | Joanna Wiensch | Buy | Upgrade | $275.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $290.00 |
| Aug 2, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $270.00 |
| Jul 26, 2024 | Stifel | Rick Wise | Buy | Maintains | $280.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 | |
| Jul 10, 2024 | Citigroup | Joanna Wiensch | Neutral | Maintains | $255.00 |
| Jul 2, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $285.00 |
| May 30, 2024 | Goldman Sachs | David Roman | Buy | Initiates | $274.00 |
| May 6, 2024 | Barclays | Travis Steed | Overweight | Maintains | $312.00 |
| Feb 5, 2024 | Barclays | Travis Steed | Overweight | Maintains | $305.00 |
| Jan 3, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $275.00 |
| Dec 4, 2023 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $280.00 |
| Nov 10, 2023 | Raymond James | Jayson Bedford | Outperform | Maintains | $269.00 |
| Nov 10, 2023 | Piper Sandler | Jason Bednar | Overweight | Maintains | $280.00 |
| Aug 21, 2023 | Citigroup | Joanna Wiensch | Neutral | Maintains | $282.00 |
| Aug 7, 2023 | Barclays | Travis Steed | Overweight | Maintains | $303.00 |
| Aug 4, 2023 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $310.00 |
| Aug 4, 2023 | Raymond James | Lawrence Keusch | Outperform | Maintains | $304.00 |
| Jul 24, 2023 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Jul 24, 2023 | Raymond James | Outperform | Upgrade | $0.00 |
Stocks Similar to Becton Dickinson and Co
The following stocks are similar to BD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Becton Dickinson and Co (BDX) Financial Data
Becton Dickinson and Co has a market capitalization of $69.71B with a P/E ratio of 40.9x. The company generates $19.83B in trailing twelve-month revenue with a 7.1% profit margin.
Revenue growth is +6.9% quarter-over-quarter, while maintaining an operating margin of +15.2% and return on equity of +5.6%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Becton Dickinson and Co (BDX) Company Overview
About Becton Dickinson and Co
Develops and sells medical supplies and devices.
The company operates through three segments: BD Medical, BD Life Sciences, and BD Interventional. It generates revenue by providing a wide range of medical devices and diagnostic products to healthcare institutions, laboratories, and the pharmaceutical industry, catering to both clinical and patient needs.
Founded in 1897 and based in Franklin Lakes, New Jersey, the company has a strong historical presence in the healthcare market. Its diverse product offerings include advanced vascular access technologies, diagnostic systems, and surgical products, positioning it as a key player in the medical supplies industry.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
70,000
CEO
Mr. Thomas E. Polen Jr.
Country
United States
IPO Year
1983
Website
www.bd.comBecton Dickinson and Co (BDX) Latest News & Analysis
Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care
23 hours agoNo specific financial information or relevant developments are provided in the news excerpt regarding Roanoke, Va., and Franklin Lakes, N.J. Please provide more details for a summary.
The mention of Roanoke and Franklin Lakes could indicate regional economic developments or partnerships affecting local businesses, potentially influencing stock performance or investment opportunities.
Investors in Medical - Dental Supplies stocks are evaluating Becton Dickinson (BDX) and Merit Medical (MMSI) for potential value opportunities.
The comparison of Becton Dickinson and Merit Medical highlights potential investment opportunities, signaling which stock may provide better value in the Medical-Dental Supplies sector.
BD (Becton, Dickinson and Company) will host an audio webcast on January 16, 2025, at 8 a.m. ET, according to their announcement.
BD's audio webcast may signal upcoming financial insights or strategic updates that could impact stock performance and investor sentiment.
BD (Becton, Dickinson and Company) announced new investments in its U.S. manufacturing to increase capacity for syringes, needles, and IV catheters, addressing healthcare demands.
BD's investment in U.S. manufacturing enhances its production capacity for essential medical devices, signaling growth potential and stability in response to healthcare demands, which could boost stock performance.
Josh Brown's 'best stocks in the market'
8 days agoJosh Brown, CEO of Ritholtz Wealth Management, shared an updated list of his top stock picks on CNBC's 'Halftime Report.'
Josh Brown's stock recommendations can influence market sentiment and provide insights into potential investment opportunities, impacting investor decisions and market movements.
Five stocks with increasing P/E ratios are Land's End, Humana, Rent the Runway, Becton, Dickinson and Company, and ATI, suggesting a unique investment strategy.
Increasing P/E ratios may signal growth potential or market optimism. These stocks could present investment opportunities or risks, influencing portfolio strategies.
Frequently Asked Questions About BDX Stock
What is Becton Dickinson and Co's (BDX) stock forecast for 2025?
Based on our analysis of 22 Wall Street analysts, Becton Dickinson and Co (BDX) has a median price target of $275.00. The highest price target is $327.54 and the lowest is $245.00.
Is BDX stock a good investment in 2025?
According to current analyst ratings, BDX has 15 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $237.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BDX stock?
Wall Street analysts predict BDX stock could reach $275.00 in the next 12 months. This represents a 15.6% increase from the current price of $237.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Becton Dickinson and Co's business model?
The company operates through three segments: BD Medical, BD Life Sciences, and BD Interventional. It generates revenue by providing a wide range of medical devices and diagnostic products to healthcare institutions, laboratories, and the pharmaceutical industry, catering to both clinical and patient needs.
What is the highest forecasted price for BDX Becton Dickinson and Co?
The highest price target for BDX is $327.54 from at , which represents a 37.7% increase from the current price of $237.92.
What is the lowest forecasted price for BDX Becton Dickinson and Co?
The lowest price target for BDX is $245.00 from Jason Bednar at Piper Sandler, which represents a 3.0% increase from the current price of $237.92.
What is the overall BDX consensus from analysts for Becton Dickinson and Co?
The overall analyst consensus for BDX is bullish. Out of 22 Wall Street analysts, 15 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $275.00.
How accurate are BDX stock price projections?
Stock price projections, including those for Becton Dickinson and Co, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
